Total Voting Rights and Capital

Click here - to use the wp menu builder

News Room

Less than 1 min.Read

By Investing Today

November 1, 2024

Octopus Apollo VCT plc

Total Voting Rights and Capital

Octopus Apollo VCT plc (‘the Company’) announces that as at 31 October 2024 its issued share capital consists of 903,052,006‬‬ ‬‬‬‬‬Ordinary shares of 0.1p each. The Company holds no shares in treasury and the total voting rights in the Company are 903,052,006‬‬‬‬.

The above figure of 903,052,006 ‬‬‬‬‬may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority’s Disclosure Guidance and Transparency Rules.

For further information please contact:

Rachel Peat
Octopus Company Secretarial Services Limited
Tel: +44 (0)80 0316 2067

LEI: 213800Y3XEIQ18DP3O53

Hot this week

Topics

Popular Categories

News RoomFeatured CompaniesVideos

Total Voting Rights and Capital

Prospera Energy Commences Restructure Initiatives at the Board Level to Attain PEI Potential

Total Voting Rights and Capital

Intel Says It Won’t Even Make $500M From Gaudi AI Chips In 2024 Despite Nvidia Minting Billions: CEO Gelsinger Says Uptake ‘Slower Than We...

Apple, Microsoft Need To Do More Than Just Beating Wall Street Estimates, Says Analyst: ‘AI Enthusiasm And Potential Is Not Enough”

Cancer-Focused ESSA Pharma Ends Prostate Cancer Trial Due to Insufficient Efficacy From Combination Therapy

LyondellBasell Q3 Results Miss Estimates, Signals Softer Demand And Rising Costs For Q4

JPMorgan To Pay Investors $151 Million After SEC Flags ‘Various Law Violations’

Topics

Intel Says It Won’t Even Make $500M From Gaudi AI Chips In 2024 Despite Nvidia Minting Billions: CEO Gelsinger Says Uptake ‘Slower Than We...

Apple, Microsoft Need To Do More Than Just Beating Wall Street Estimates, Says Analyst: ‘AI Enthusiasm And Potential Is Not Enough”

Cancer-Focused ESSA Pharma Ends Prostate Cancer Trial Due to Insufficient Efficacy From Combination Therapy

LyondellBasell Q3 Results Miss Estimates, Signals Softer Demand And Rising Costs For Q4

JPMorgan To Pay Investors $151 Million After SEC Flags ‘Various Law Violations’

Why Charter Communications Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket

Popular Weight Loss Drug Wegovy Shows Encouraging Results in Liver Fibrosis Trial

K12 Announces Winners of its 2024 Photography Competition

Related Articles

Intel Says It Won’t Even Make $500M From Gaudi AI Chips In 2024 Despite Nvidia Minting Billions: CEO Gelsinger Says Uptake ‘Slower Than We...

Apple, Microsoft Need To Do More Than Just Beating Wall Street Estimates, Says Analyst: ‘AI Enthusiasm And Potential Is Not Enough”

Cancer-Focused ESSA Pharma Ends Prostate Cancer Trial Due to Insufficient Efficacy From Combination Therapy

LyondellBasell Q3 Results Miss Estimates, Signals Softer Demand And Rising Costs For Q4

JPMorgan To Pay Investors $151 Million After SEC Flags ‘Various Law Violations’

Company

Headlines

Intel Says It Won’t Even Make $500M From Gaudi AI Chips In 2024 Despite Nvidia Minting Billions: CEO Gelsinger Says Uptake ‘Slower Than We...

Apple, Microsoft Need To Do More Than Just Beating Wall Street Estimates, Says Analyst: ‘AI Enthusiasm And Potential Is Not Enough”

Cancer-Focused ESSA Pharma Ends Prostate Cancer Trial Due to Insufficient Efficacy From Combination Therapy

LyondellBasell Q3 Results Miss Estimates, Signals Softer Demand And Rising Costs For Q4

Newsletter